Switch theme
Sign up to access all valuation multiples
AGP Ltd is a pharmaceutical company engaged in manufacturing and marketing of products under licensing arrangements with other pharmaceutical companies. The company has two manufacturing facilities situated in the S.I.T.E industrial area, Karachi, Pakistan. Its key products include Nergab, Afdol, Nebcin among others.
2014
2.1K+
LTM Revenue $97.6M
LTM EBITDA n/a
$237M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
AGP Pharma has a last 12-month revenue of $97.6M and a last 12-month EBITDA of n/a.
In the most recent fiscal year, AGP Pharma achieved revenue of $89.4M and an EBITDA of $26.5M.
AGP Pharma expects next 12-month revenue of XXX and NTM EBITDA of XXX
See AGP Pharma valuation multiples based on analyst estimates| FY 2023 | FY 2024 | FY 2025 | LTM | NTM | |
|---|---|---|---|---|---|
| Revenue | $66.9M | $89.4M | XXX | XXX | XXX |
| Gross Profit | $26.2M | $35.9M | XXX | XXX | XXX |
| Gross Margin | 39% | 40% | XXX | XXX | XXX |
| EBITDA | $16.3M | $26.5M | XXX | XXX | XXX |
| EBITDA Margin | 24% | 30% | XXX | XXX | XXX |
| Net Profit | $5.6M | $5.6M | XXX | XXX | XXX |
| Net Margin | 8% | 6% | XXX | XXX | XXX |
| Net Debt | $8.4M | $39.0M | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of April 15, 2025, AGP Pharma's stock price is PKR 200 (or $1).
AGP Pharma has current market cap of PKR 56.1B (or $200M), and EV of PKR 66.2B (or $237M).
See AGP Pharma trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $237M | $200M | XXX | XXX | XXX | XXX | $0.04 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Sign UpAs of April 15, 2025, AGP Pharma has market cap of $200M and EV of $237M.
AGP Pharma's trades at 2.4x LTM EV/Revenue multiple, and n/a LTM EBITDA.
Analysts estimate AGP Pharma's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See valuation multiples for AGP Pharma and 10K+ public comps| FY 2024 | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|
| EV | $237M | XXX | XXX | XXX |
| EV/Revenue | 2.6x | XXX | XXX | XXX |
| EV/EBITDA | 8.9x | XXX | XXX | XXX |
| P/E | 21.0x | XXX | XXX | XXX |
| P/E/Growth | n/a | XXX | XXX | XXX |
| EV/FCF | 14.9x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Sign UpAGP Pharma's NTM/LTM revenue growth is 17%
AGP Pharma's revenue per employee for the last fiscal year averaged $42K, while opex per employee averaged $13K for the same period.
Over next 12 months, AGP Pharma's ratio of sales and marketing spend to revenue is estimated to be XXX , while its R&D spend to revenue to be XXX .
Analysts estimate AGP Pharma's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See operational valuation multiples for AGP Pharma and other 10K+ public comps| FY 2024 | NTM | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|---|
| Revenue Growth | 34% | XXX | XXX | XXX | XXX |
| EBITDA Margin | 30% | XXX | XXX | XXX | XXX |
| EBITDA Growth | 63% | XXX | XXX | XXX | XXX |
| Rule of 40 (SaaS-only) | 46% | XXX | XXX | XXX | XXX |
| Revenue per Employee | $42K | XXX | XXX | XXX | XXX |
| Opex per Employee | $13K | XXX | XXX | XXX | XXX |
| S&M Expenses to Revenue | 12% | XXX | XXX | XXX | XXX |
| G&A Expenses to Revenue | 1% | XXX | XXX | XXX | XXX |
| R&D Expenses to Revenue | 1% | XXX | XXX | XXX | XXX |
| Opex to Revenue | 30% | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Benevolent AI | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
AGP Pharma acquired XXX companies to date.
Last acquisition by AGP Pharma was XXXXXXXX, XXXXX XXXXX XXXXXX . AGP Pharma acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Sign Up| When was AGP Pharma founded? | AGP Pharma was founded in 2014. |
| Where is AGP Pharma headquartered? | AGP Pharma is headquartered in Pakistan. |
| How many employees does AGP Pharma have? | As of today, AGP Pharma has 2.1K+ employees. |
| Is AGP Pharma publicy listed? | Yes, AGP Pharma is a public company listed on KAR. |
| What is the stock symbol of AGP Pharma? | AGP Pharma trades under AGPL ticker. |
| When did AGP Pharma go public? | AGP Pharma went public in 2018. |
| Who are competitors of AGP Pharma? | Similar companies to AGP Pharma include e.g. Julphar, Benevolent AI, Galapagos, Pharming. |
| What is the current market cap of AGP Pharma? | AGP Pharma's current market cap is $200M |
| What is the current revenue of AGP Pharma? | AGP Pharma's last 12-month revenue is $97.6M. |
| What is the current EV/Revenue multiple of AGP Pharma? | Current revenue multiple of AGP Pharma is 2.4x. |
| What is the current revenue growth of AGP Pharma? | AGP Pharma revenue growth between 2023 and 2024 was 34%. |
| Is AGP Pharma profitable? | Yes, AGP Pharma is EBITDA-positive (as of the last 12 months). |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
